tucatinib
Pfizer Acquires Seagen in $43B Deal
Pfizer will gain Seagen's anti-HER2 therapy Tukysa along with its pipeline of oncology drug candidates.
FDA Approves Seagen's Tukysa, Genentech's Herceptin for HER2-Positive Colorectal Cancer Patients
The agency granted the dual anti-HER2 regimen accelerated approval as a second-line option for advanced colorectal cancer patients based on data from the MOUNTAINEER trial.
Seagen Going After Tukysa, Herceptin Combo Approval in HER2-Positive Colorectal Cancer
The company plans to seek accelerated approval for the regimen after seeing a 38 percent objective response rate in the MOUNTAINEER trial.
NICE Recommends Seagen's Tukysa for Advanced HER2-Positive Breast Cancer in England
The body has changed its mind based on new data and a discounted price and is now recommending Tukysa plus Herceptin and capecitabine in this setting.
SABCS Clinicogenomic Study Sheds Light on HER2-Targeted Therapy Resistance
Genomic sequencing on 733 HER2-positive advanced breast cancer patients revealed mechanisms of anti-HER2 treatment resistance and potential therapeutic solutions.